Universal Health Services arrives at its Q2 earnings on July 28 with options traders holding their most call-heavy positioning in months — even as short sellers have quietly added pressure in the final days before the release.
The options signal is the sharpest data point, and it is decisively bullish. The put/call ratio has fallen to 0.48, more than two standard deviations below its 20-day average of 0.74. That is the lowest PCR reading of the past year, outside the 52-week floor of 0.39. The stock has tracked that optimism: UHS is up 9% over the past month to $159.31, adding another 2.3% on Monday and 5.8% on the week. The borrow market offers no squeeze threat to complicate the picture — availability is exceptionally loose at roughly 13x current short interest, and the cost to borrow has eased roughly a third over the past month to under 0.40%.
Short interest tells a more cautious supporting story. Bears have been adding with conviction in the final stretch. Short interest jumped 12% in a single session on July 24 and is up nearly 13% on the week, lifting the float-short ratio to 6.2% — its highest level in the 30-day window. That move is notable: it runs directly against the call-heavy options positioning, suggesting some traders are fading the pre-earnings optimism even as the broader market leans long. The ORTEX short score has ticked up to 44.2, its highest reading in the recent history, reflecting that accumulation of fresh short positions.
The analyst community has been trimming rather than capitulating. Guggenheim cut its target to $195 last week while holding its Buy rating, and Barclays downgraded to Equal-Weight earlier this month with a $179 target. Wells Fargo, also at Equal-Weight, nudged its target marginally higher to $166. The mean target of around $205 implies roughly 29% upside from current levels, but the direction of travel has been downward — several firms slashed targets sharply after the Q1 miss in late April, when the stock fell 2.4% on the day and lost 7.3% over the following five sessions. The debate has not changed materially since: bulls back UHS's behavioral health franchise and the long-term volume ramp, arguing margins should improve as new assets mature. Bears point to the Q1 execution shortfall — core EBITDA fell 4% against a 5% growth target — and argue the elongated ramp path deserves a lower multiple. THC surged 17% on the day and nearly 20% on the week, suggesting at least some positive read-through for hospital operators from recent prints, though UHS's behavioral mix makes it a different story.
The Q2 print is therefore a direct test of whether the behavioral volume acceleration management has been promising has finally arrived, or whether the ramp disappointment that defined Q1 extends into a second consecutive quarter.
See the live data behind this article on ORTEX.
Open UHS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
